OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$1.02
Market Cap
$345.89M
52W High
$2.72
52W Low
$0.97
ADV30
6,935,513
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,488,000 | — | -16,444,000 | -24,877,000 | 124,206,000 | 100,051,000 | 140,762,000 |
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
| Sep 2025 | 1,752,000 | — | -17,625,000 | -20,051,000 | 57,596,000 | 32,565,000 | 54,063,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,869,000
Investing CF
$-148,000
Financing CF
$133,864,000
CapEx
$-153,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-452,121,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-73,369,000
Pretax Income TTM
$-81,811,000
Interest Exp TTM
$8,442,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,581,000
EBITDA
$-67,173,000
Free Cash Flow
$-1,974,375
Enterprise Value
$333,827,616
Total Cash
$100,051,000
Total Debt
$87,986,000
Shares Out
339,110,401
Trailing EPS
$-0.26
Book Value
$-0.05
ROE
-660.0%
ROA
-48.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | -12,166,000 | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | 29,632,000 | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | 40,564,000 | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | 73,981,000 | -60,079,000 |
TTM Snapshot
Revenues TTM
$1,136,000
NetIncome TTM
$-12,970,000
OpCashFlow TTM
$0
Assets (Latest)
$82,442,000
Forward EPS
$-0.27
Max Pain — expiry 2026-10-16
max pain strike: $1.00 · spot: $1.01 · call oi: 8,939 · put oi: 7,857
Expected Move to 2026-10-16:
±$0.18
(17.33%) —
implied range
$0.83 –
$1.18
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRZN | Surrozen, Inc./DE | $347.20M | $29.54 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $341.74M | $6.99 | — |
| CABA | Cabaletta Bio, Inc. | $350.96M | $2.07 | — |
| PROK | PROKIDNEY CORP. | $334.28M | $1.60 | — |
| CCCC | C4 Therapeutics, Inc. | $366.61M | $2.98 | — |
News headlines (Yahoo Finance, 1h cache)
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
2026-09-25 12:51 · Yahoo
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
2026-09-25 11:02 · Yahoo
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
2026-09-16 04:02 · Yahoo
Ocugen to Participate in Upcoming September Investor and Industry Conferences
2026-08-25 11:02 · Yahoo
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
2026-08-16 01:01 · Yahoo
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
2026-08-13 18:14 · Yahoo
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
2026-08-07 17:18 · Yahoo
Ocugen Q2 Earnings Call Highlights
2026-08-07 06:04 · Yahoo
Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ...
2026-08-06 23:15 · Yahoo
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
2026-09-25 17:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.